Table 1.
Baseline characteristics by treatment group in 100 subjects with grass-pollen induced allergic rhinitis in a randomized placebo-controlled double-blind clinical trial of T. suis for grass-pollen allergy, Denmark, 2008.
Figure 1.
Daily prevalence of subjects who reported gastrointestinal symptoms.
(A) by number of days participating in a randomized double-blind clinical trial of three-weekly ingestions of infective T. suis eggs (N = 49, red/bold line) and placebo (N = 47, blue/grey line), along with corresponding figures for subjects who reported severe (B), moderate (C) and mild (D) gastrointestinal symptoms, Denmark, 2008. Vertical lines represent days of clinic visits (three-weekly) when subjects were to ingest 2500 live T. suis eggs or placebo except on visit day 168 (total 8 doses).
Table 2.
Rate ratios (RR) for first adverse event according to System Organ Class by treatment group in a randomized double-blind clinical trial of T. suis and placebo, Denmark, 2008.
Table 3.
Rate ratio (RR) of gastrointestinal adverse events according to maximum severity and type by days and treatment group in a randomized double-blind clinical trial of T. suis and placebo, Denmark, 2008.
Figure 2.
Incidence of gastrointestinal symptoms after three-weekly ingestions of infective T. suis eggs by 49 subjects, and placebo by 47 subjects, in a randomized placebo-controlled double-blinded clinical trial, Denmark 2008.
Vertical lines represent days of clinic visits (three-weekly) when subjects were to ingest 2500 live T. suis eggs or placebo except on visit day 168 (total 8 doses). Each horizontal thin line represents a subject. Episodes of each subject are indicated by grey (moderate) and black (severe) horizontal thick lines. “X”, the subject ingested no eggs/placebo due to gastrointestinal symptoms; “#”,the subject ingested no eggs/placebo due to reasons unrelated to the intervention; “O”, the subject stopped recording diary of symptoms before end of trial.
Table 4.
Rate ratio of first moderate to severe gastrointestinal symptoms (before day 63) within strata of characteristics in a randomized placebo-controlled double-blind clinical trial of T. suis for grass-pollen allergy, Denmark, 2008.
Figure 3.
Level of serum IgG against adult T. suis excretory/secretory antigen over time according to severity of gastrointestinal symptoms after three-weekly ingestion of infective T. suis eggs by 49 subjects in a randomized placebo-controlled double-blind clinical trial in grass-pollen allergic adults, Denmark 2008.
Within subgroups of severity, data circles are positioned by severity (None, left; Mild, right), (Moderate, left; Severe, right). Blood was drawn times 3 (blood visit 1 at start (not shown, no IgG response)), blood visit 2 during grasspollen season (1st period and 2nd period), and blood visit 3 at end of study), and diary was kept day 0–168, except in 4 subjects indicated by circles in figure A: 2 subjects (severe) dropped out (moved abroad, no time) between blood visit 2 (day ∼90) and 3, however recorded diary until day ∼90; 2 other subjects (moderate, severe) recorded diary until blood sampling visit 2 (day ∼59) or longer (>day 90) although they did not attend blood visit 3. * P<0.05.
Table 5.
Median value of blood parameters over time according to severity of gastrointestinal symptoms after ingestion of whipworm T. suis eggs (N = 49) in a randomized double-blind clinical trial of T. suis for grass-pollen allergy, Denmark, 2008.